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Abstract
Understanding the role of lipids in synapses and the aberrant
molecular mechanisms causing the cognitive deficits that charac-
terize most lipidosis is necessary to develop therapies for these
diseases. Here we describe sphingomyelin (SM) as a key modula-
tor of the dendritic spine actin cytoskeleton. We show that
increased SM levels in neurons of acid sphingomyelinase knock
out mice (ASMko), which mimic Niemann Pick disease type A
(NPA), result in reduced spine number and size and low levels of
filamentous actin. Mechanistically, SM accumulation decreases
the levels of metabotropic glutamate receptors type I (mGluR1/5)
at the synaptic membrane impairing membrane attachment and
activity of RhoA and its effectors ROCK and ProfilinIIa. Pharma-
cological enhancement of the neutral sphingomyelinase rescues
the aberrant molecular and morphological phenotypes in vitro
and in vivo and improves motor and memory deficits in ASMko
mice. Altogether, these data demonstrate the influence of
SM and its catabolic enzymes in dendritic spine physiology
and contribute to our understanding of the cognitive deficits
of NPA patients, opening new perspectives for therapeutic
interventions.
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Introduction
Alterations in dendritic spines, protrusions at the postsynaptic
membrane that receive most of the excitatory input in the central
nervous system (Yuste & Tank, 1996), have been related to many
cognitive disorders (Carlisle & Kennedy, 2005). Dynamic changes
in spine shape, size and number upon stimuli is essential in learn-
ing and memory processes (Yuste & Bonhoeffer, 2001). The actin
cytoskeleton, enriched in the spines, regulates the spine dynamism
(Frost et al, 2010). Intense research in recent years has led to a
detailed knowledge on the protein machinery interacting with
actin that modulates the dynamics of spine morphology, which
includes extracellular ligands, neurotransmitter receptors, scaffold
proteins, the Rho family of small GTPases and proteins that
directly control actin polymerization (Tada & Sheng, 2006). How-
ever, much less is known about the role of lipids in these pro-
cesses. This is especially relevant considering that the remodelling
of the postsynaptic membrane, of which lipids are major compo-
nents, is as remarkable as that of the underlying cytoskeleton in
spine plasticity. Moreover, the activity of key proteins in synaptic
remodelling depends on their interaction with the membrane. Fur-
ther support for a key role of lipids in spine dynamics comes from
the fact that genetic defects affecting lipid metabolism, and leading
to lipidosis, frequently cause cognitive impairment (Futermann &
Van Meer, 2004).
Sphingolipids are major components of neuronal membranes,
where they are particularly enriched (Schwarz et al, 1995). Mount-
ing evidence indicates that these lipids actively participate in essen-
tial functions including signaling (Simons & Toomre, 2000),
proteolysis (Ledesma et al, 2003), endocytosis (Parton & Richards,
2003) and the establishment and maintenance of axonal polarity
(Ledesma et al, 1999; Galvan et al, 2005). Sphingolipids are also
involved in the formation and/or maintenance of dendritic spines.
Thus, pharmacological inhibition of sphingolipids led to dendritic
spine alterations in cultured primary hippocampal neurons (Hering
et al, 2003). In addition, biochemical and microscopy studies have
indicated that the localization of several postsynaptic proteins,
including scaffold proteins and neurotransmitter receptors, also
depend on sphingolipids (Bruses et al, 2001; Hering et al, 2003).
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However, the molecular mechanisms by which sphingolipids exert
these effects are largely unknown.
Niemann Pick disease type A (NPA) is a sphingolipidosis caused
by loss of function mutations in the SMPD1 gene encoding for the
acid sphingomyelinase (ASM). NPA leads to severe and early onset
neurodegeneration (Brady et al, 1966) for which no treatment is yet
available. ASM participates in sphingolipid metabolism by hydrolyz-
ing SM (Stoffel, 1999). In mice that lack this enzyme (ASMko),
whose phenotype mimics the human disease (Horinouchi et al,
1995), SM accumulates at the neuronal plasma membrane leading
to impaired endocytosis and mislocalization of GPI-anchored pro-
teins (Galvan et al, 2008). Moreover, accumulation of SM and its
derivative sphingosine also occurs at the presynaptic membranes
of mutant mice causing alterations in synaptic vesicle docking
and presynaptic plasticity events (Camoletto et al, 2009). In the
present study we have analyzed ASMko mice to investigate
whether and how altered sphingolipid levels affect dendritic
spines and if sphingolipid modulation could become a suitable
treatment for NPA. The results indicate that high SM levels due
to ASM deficiency reduce the number and size of dendritic
spines. In addition, we provide evidence for the molecular mecha-
nism underlying these alterations and novel strategies to revert
them in vitro and in vivo.
Results
Lack of ASM reduces dendritic spine number and size
To investigate the effects on dendritic spines of loss of function
mutations of the SMPD1 gene, encoding for ASM, we analyzed these
structures in vivo by diOlistic fluorescent labelling of brain sections
through the S1 cortex and the hippocampal formation of age-
matched wild type (wt) and ASMko mice. We chose to analyze
these brain areas because of their involvement in learning and mem-
ory abilities, which are impaired in NPA patients. Confocal stacks
z-projections from segments of secondary apical dendrites of
somatosensory cortical and CA1 hippocampal pyramidal neurons
were used for the quantitative analyses of dendritic spines (Fig 1A).
The number of spines identified with DiI labelling per micrometer of
dendrite length was significantly reduced in the layer 1 (L1) of the
S1 cortex of ASMko brains compared to wt (wt: 1.56  0.01 spines/
lm; ASMko: 0.95  0.07 spines/lm). Although there was a similar
tendency to reduction in the CA1 pyramidal neurons of the hippo-
campus in ASMko mice the difference in the number of dendritic
spines between genotypes was not statistically significant in this
area (wt: 1.80  0.11 spines/lm; ASMko: 1.60  0.14 spines/lm).
To accurately analyze not only the number but also the size of
the spines, we performed electron microscopy analysis in stratum
radiatum of the hippocampal CA1 region of age matched wt
and ASMko mice (Fig 1B). While the number of spines did not
change significantly (wt: 2.20  0.3 synapses/lm3; ASMko:
2.22  0.29 synapses/lm3), in agreement with the diOlistic analysis
data, the area of the postsynaptic compartment was smaller in ASM-
ko conditions (wt: 0.16  0.012 lm2; ASMko: 0.09  0.009 lm2).
Accordingly, the length of the postsynaptic density was significantly
reduced (wt: 0.29  0.003 lm; ASMko: 0.24  0.006 lm). Den-
dritic spine size was also reduced in the cerebellum of ASMko mice
(wt: 0.33  0.002 lm; ASMko: 0.27  0.002 lm) (Supplementary
Fig 1A). Altogether these results show that the absence of ASM has
a broad impact in dendritic spines of different neuronal populations
ranging from spine loss in the cortex to reduced size in the hippo-
campus and cerebellum.
Reduced levels of filamentous actin in ASMko dendritic spines
due to SM accumulation
Because of the key role of the actin cytoskeleton in dendritic spine
size we compared actin polymerization in primary hippocampal
neuron cultures derived from wt and ASMko mice by phalloidin
staining. Phalloidin associated fluorescence, which is specific for
filamentous actin, was 1.55-fold reduced in ASMko compared to wt
dendritic spines (Fig 1C). Our next aim was to understand the
molecular mechanism underlying this aberrant phenotype. Lack of
ASM leads to the accumulation of SM in total synaptosomal mem-
branes (Camoletto et al, 2009). To test to which extent this affects
the postsynaptic compartment an additional step was taken in the
synaptosome isolation protocol so to obtain a fraction highly
enriched in postsynaptic membranes (Schubert et al, 2006)
(Fig 2A). Mass analysis of different lipids in this fraction (see meth-
ods) indicated that while the levels of phospholipids (wt:
35  7 nmol/mg protein; ASMko: 40  4 nmol/mg protein) or cho-
lesterol (wt: 287  52 nmol/lmol phospholipids; ASMko:
298  25 nmol/lmol phospholipids) did not show significant differ-
ences, a two-fold increase in SM (wt: 108  21 nmol/lmol phos-
pholipids; ASMko: 225  4 nmol/lmol phospholipids) occurred in
the postsynaptic fraction obtained from ASMko brains compared to
wt (Fig 2A). To test whether high SM levels could account for the
actin alterations observed in the spines, this lipid was added to
cultured hippocampal neurons from wt mice. We increased SM
amount without significantly affecting levels of cholesterol/
phospholipids or the viability of the cells (see Materials and
Methods and Galvan et al, 2008). Phalloidin staining in the spines
was 1.38-fold diminished compared to non-treated neurons
(Fig 2B). In addition, ASMko cultured neurons were treated with
exogenous sphingomyelinase. This treatment restored SM amount
to levels similar to wt without changing cholesterol/phospholipid
amount or inducing cell death (see Materials and Methods and
Galvan et al, 2008). Phalloidin staining in spines was 1.45-fold
increased reaching levels similar to those in wt neurons (Fig 2C).
These findings indicated a direct relationship between SM accumu-
lation and dendritic spine alterations. Moreover, they pointed to low
levels of filamentous actin as a cause for the reduced size of ASMko
dendritic spines.
Membrane attachment of RhoA and its effectors are reduced in
ASMko synaptosomes due to high SM levels
The small GTPases of the Rho family, cdc42, RhoA and Rac1 and
their effectors are major modulators of actin polymerization in den-
dritic spines (Tada & Sheng, 2006). To test whether alterations in
these proteins could account for the low levels of filamentous actin
found in ASMko spines, their amount and membrane attachment,
which is necessary for their activation (Buchsbaum, 2007), were
compared in synaptosomal fractions of wt and ASMko mice brains.
Total levels and membrane attachment were similar for cdc42 and
Ana I Arroyo et al Synaptic rescue in Niemann Pick type A EMBO Molecular Medicine
ª 2014 The Authors EMBO Molecular Medicine Vol 6 | No 3 | 2014 399
Rac1 (Supplementary Fig 2). In contrast, total RhoA levels in ASMko
conditions were reduced (28% lower than in wt) (Fig 3Aa). A
greater reduction (51%) was evident in the amount of RhoA bound
to the membrane (Fig 3Ab). Consistently, we found low amounts of
active RhoA, determined by the ability to bind Rhotekin (38% less
RhoA bound to Rhotekin in ASMko samples compared to wt)
(Fig 3Ba). Because RhoA enhances the stability of filamentous actin
in dendritic spines through complexing with its downstream
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Figure 1. Aberrant dendritic spines and low levels of filamentous actin in ASMko neurons.
A Dendritic spines in dendrites of neurons from the S1-L1 cortex of wt and ASMko mice visualized by diOlistics and confocal microscopy. Graphs show dendritic spine
density per lm of dendritic segments in the S1-L1 cortex (P = 0.01) or the CA1 region of the hippocampus (n = 4). Bar 5 lm.
B Electron micrographs of synapses in the hippocampal CA1 stratum radiatum of wt and ASMko mice. Spines are indicated by asterisks. Graphs show mean and
standard deviation (mean  s.d.) of spine size in lm2 (P = 0.016) and PSD length in lm (P = 0.006) in wt and ASMko mice (n = 70 synapses in each of 3 mice per
genotype).
C Top: Dendrites from wt or ASMko cultured hippocampal neurons stained for MAP2 (blue), PSD95 (red), and phalloidin (green); bottom: phalloidin staining only. The
graph shows mean  s.d. of phalloidin fluorescence intensity per spine area (n = 250 dendritic spines from 3 independent cultures, P = 0,011). Bars: 5 lm.
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effectors RhoA-specific kinase (ROCK) and profilinIIa (Schubert
et al, 2006) we monitored the membrane-bound amount of these
molecules. In agreement with reduced filamentous actin, ASMko
synaptosomal membranes presented significantly lower levels of
ROCK and profilinIIa than those wt (81 and 68% reductions, respec-
tively) (Fig 3Bb). To investigate if the alterations in the RhoA path-
way could be due to SM accumulation we modulated the levels of
this lipid. On one hand, we added SM to wt synaptosomes achieving
a 2.1- fold increase in the lipid levels of synaptic membranes similar
to the ASMko situation (Fig 3Ca) (see methods and Camoletto et al,
2009). SM addition resulted in 46% reduction of RhoA membrane
attachment (Fig 3Cb). The levels of membrane-bound RhoA effec-
tors ROCK and profilinIIa were also reduced significantly (79 and
31%, respectively) (Fig 3Cc,d). On the other hand, sphingomyelinase
treatment of ASMko synaptosomes reduced SM levels and
increased RhoA membrane binding by 3- and 4.5- fold, respectively
(Supplementary Fig 3).
Altogether these data show the influence in synapses of SM lev-
els in the RhoA pathway, which is a key modulator of actin polimer-
ization in dendritic spines (Schubert et al, 2006).
mGluR1/5 levels and interaction with RhoA are reduced in
ASMko synaptosomes
RhoA can associate with the plasma membrane in dendritic spines
through its interaction with Group I metabotropic glutamate recep-
tors (mGluR1/5). This interaction is enhanced upon stimuli
(Schubert et al, 2006). Moreover, mGluR1/5 localize to cholesterol-
sphingolipid membrane domains (Francesconi et al, 2009), which
show altered composition in ASMko neuronal membranes (Galvan
et al, 2008). Hence, we hypothesized that alterations in mGluR1/5
could account for the reduced RhoA attachment to the ASMko syn-
aptic membrane and thus activation. To test this hypothesis, the lev-
els of these receptors were compared in wt and ASMko
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Figure 2. High SM levels accumulate in ASMko postsynaptic membranes and reduce the amount of filamentous actin.
A Western blots of the presynaptic and postsynaptic markers synaptophysin (Sy38) and PSD 95, respectively, in extracts containing the same amount of protein from
total synaptosomal preparation (Syn) and from the postsynaptic enriched fraction (PSD). Graphs show mean  s.d. of the levels of SM (P = 0.011) and cholesterol
(in nmol/lmol phospholipids) and of phospholipids (nmol/mg protein) in postsynaptic membranes (PSD fraction) of wt and ASMko mice (n = 6).
B,C Top: Dendrites from cultured hippocampal neurons from wt mice treated or not with SM (B) or from ASMko mice treated or not with SMase (C) stained for MAP2
(blue), PSD95 (red), and phalloidin (green); bottom: phalloidin staining only. The graphs show mean  s.d. of phalloidin fluorescence intensity per spine area
(n = 250 dendritic spines from 3 independent cultures, *Pwt+SM = 0.02; *Pko+Smase = 0.03). Bars: 5 lm.
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Figure 3. Absence of ASM and SM modulation alter the levels and activity of RhoA and its effectors in synaptosomes.
A Western blot of RhoA and tubulin levels in total (a) and membrane extracts (b) from wt and ASMko synaptosomes. Graphs show mean  s.d. of RhoA levels in ASMko
conditions normalized to tubulin and referred to wt levels that were considered as 1 (n = 3, *Ptotal RhoA = 0.04, *Pmembrane RhoA = 0.008).
B (a) Activity of RhoA in wt and ASMko synaptosomes determined by the Rhotekin binding assay. Tubulin is shown as loading control. Graph shows mean  s.d. of the
ratio of Rhotekin-bound (active) RhoA to total RhoA (n = 3, *P = 0.025). (b) Western blots of ROCK, ProfilinIIa and tubulin levels in membrane extracts from wt and
ASMko synaptosomes. Graphs show mean  s.d. of ROCK (*P = 0.017) or ProfilinIIa (*P = 0.033) levels in ASMko conditions normalized to tubulin and referred to wt
levels that were considered as 1 (n = 3).
C (a) SM levels (nmol/mg protein) in wt synaptosomes treated or not with SM. Graph shows mean  s.d. in treated synaptosomes referred to non treated that were
considered as 1 (n = 3, **P = 0.019). (b, c, d) Western blots of RhoA (b), ROCK (c) and ProfilinIIa (d) levels in supernatants (S) and pellets (P) after 100,000 g
centrifugation of wt synaptosomes treated or not with SM. Graphs show mean  s.d. of each protein ratio pellet/supernatant in treated samples referred to non-
treated that were considered as 1 (n = 3; *PRhoASM = 0.029, ***PROCKSM = 0.0009, **PprofilinIIaSM= 0.008).
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synaptosomes. Both mGluR1 and mGluR5 showed a significant
reduction in ASMko conditions (43 and 80%, respectively) (Fig 4A).
That increased SM levels are responsible for such deficiency was
strongly supported by the 29 and 39% decrease found in the levels
of mGluR1 and mGluR5, respectively, in wt synaptosomes treated
with this lipid compared to non-treated synaptosomes (Fig 4B).
To further assess our hypothesis on the altered interaction
between mGluR1/5 and RhoA we performed immunoprecipitation
assays. We observed that the enhanced RhoA-mGluR1/5 interac-
tion in wt synaptosomes upon stimulation was not achieved in
stimulated ASMko synaptosomes (Fig 4Ca,b). Consistently, RhoA
activity increased upon stimulation in wt synaptosomes (1.3-fold
respect to non-stimulated wt synaptosomes) as demonstrated by
a Rhotekin binding assay. This stimulus-induced increase in
active RhoA levels did not occur in ASMko conditions (0.75-fold
in stimulated with respect to non-stimulated ASMko synapto-
somes) (Fig 4Cc). Altogether, these results point to the contribu-
tion of SM-induced reduction of mGluR1/5 levels to the
impaired RhoA membrane attachment and activation in ASMko
synapses.
Reduction of SM levels by activation of neutral sphingomyelinase
(NSM) restores RhoA membrane binding and filamentous actin
levels in ASMko synapses in vitro
The results reported so far pointed to SM accumulation at the
synaptic membrane as responsible for the alterations in RhoA
leading to cytoskeletal actin anomalies in dendritic spines lacking
ASM. To further demonstrate this point and to search for rescue
strategies, we next aimed to reduce SM levels by activating NSM,
which is the main responsible for SM hydrolysis at the plasma
membrane (Stoffel, 1999) and contributes to synaptic plasticity
(Wheeler et al, 2009). To determine whether NSM could be a
suitable target to modulate SM levels at ASMko synaptic mem-
branes we first determined the levels of this enzyme at synapses.
NSM showed similar levels at synaptic and total membranes from
wt and ASMko mice brains (Fig 5A). The active form of Vitamin
D3 (1a, 25-dihydroxyvitamin D3) and the synthetic steroid hor-
mone dexamethasone have been shown to increase NSM activity,
reducing SM levels in non neuronal cell cultures (Okazaki et al,
1989; Ramachandran et al, 1990). Hence, we incubated ASMko
synaptosomes with 0.1 lM 1a, 25-dihydroxyvitamin D3 or dexa-
methasone for 1 h at 37°C. The treatments resulted in 25 and
41% decrease in SM levels, respectively (Fig 5B). Indicative of
the involvement of NSM in these effects we observed a significant
30 and 15% increase in NSM protein and activity levels, respec-
tively, upon dexamethasone treatment (Fig 5C) (NSM protein lev-
els were also increased (17%) by 1a, 25-dihydroxyvitamin D3
treatment although in this case the change was not significant).
1a, 25-dihydroxyvitamin D3 and dexamethasone treatments
enhanced RhoA binding to the ASMko synaptic membrane by
1.98 and 4-fold, respectively (Fig 5D) but had no effect in synap-
tosomes derived from wt mice where SM levels were also unal-
tered (Supplementary Fig 4A and B).
To assess the effect of enhanced NSM levels and SM reduction
on actin polymerization we incubated cultured hippocampal neu-
rons derived from ASMko mice with 0.1 lM 1a, 25-dihydroxy-
vitamin D3 or dexamethasone. The treatments started at 9 days in
vitro (DIV) and went on until 15DIV when cultured neurons are
fully mature and dendritic spines are evident. We observed 39 and
117% increments in the filamentous actin levels of spines in the
ASMko treated neurons with 1a, 25-dihydroxyvitamin D3 or dexa-
methasone, respectively, as monitored by phalloidin staining
(Fig 5E). We did not observe significant effects on filamentous actin
in dendritic spines of similarly treated wt neurons (Supplementary
Fig 4C). In all, these results further supported the role of SM and
NSM in ASMko dendritic spine actin modulation and provided with
a pharmacological strategy to revert spine abnormalities in the
mouse model for NPA.
Oral administration of dexamethasone reverts SM and RhoA
synaptic anomalies, restores dendritic spine size, prevents
neuronal death and improves functional deficits in ASMko
females
Our next aim was to test the efficiency of the aforementioned treat-
ments in vivo. Since dexamethasone showed more pronounced
effects on the in vitro reversion of aberrant molecular phenotypes
we chose to use this synthetic glucocorticoid, which is able to cross
the brain blood barrier (Stumpf et al, 1989; Stumpf, 2012) and is
currently used for the treatment of different human diseases (van de
Beek et al, 2012; De Cassan et al, 2012; Kanwar et al, 2013). Treat-
ments started immediately after weaning in 1-month old wt and
ASMko mice. Dexamethasone dissolved in ethanol was added to the
drinking water at a concentration that ensured the consumption per
mouse of 0.3 lg/g/day, which is a dose utilized for long term treat-
ment in pediatric patients. Wt and ASMko mice were divided by
gender in groups of ten animals each. Non-treated males and
females were given ethanol in their drinking water at the same con-
centration than the dexamethasone-treated mice (0.1% v/v). Treat-
ments were followed for 2.5 months. At the end of this period mice
were sacrificed and synaptosomes were obtained. Dexamethasone
treatment of wt mice did not alter SM levels nor RhoA membrane
binding in synaptosomes (Supplementary Fig 4D). Among the
treated ASMko males 50% of them showed reduced SM levels com-
pared with non-treated ASMko males but the average reduction was
a non-significant 16% (Supplementary Fig 5A). Also non significant
were the changes in NSM protein levels and the 1.3-fold increase in
RhoA membrane attachment in synaptosomes of dexamethasone
treated ASMko males (Supplementary Fig 5B and C). However, all
treated ASMko females showed SM reduction at their synaptic mem-
branes, which in average reached a significant 36.7% compared to
non-treated ASMko females (Fig 6A). That SM reduction was driven
by NSM in vivo was supported by the dexamethasone-induced
113% increase in the enzyme levels (Fig 6A). This was accompa-
nied by the transcriptional upregulation of the enzyme, which
mRNA levels were two-fold higher in brain extracts from dexa-
methasone treated ASMko females (Fig 6A). In turn, RhoA mem-
brane binding was enhanced by 1.7-fold (Fig 6B). Electron
microscopy analysis showed a significant 36% increase in the PSD
length of synapses of the hippocampal CA1 region in the ASMko
treated females (Fig 6C). To determine whether other neuropatho-
logical changes were improved by the treatment we monitored neu-
ronal death in the cerebellum, which is a pathological hallmark in
ASMko mice brains already at 3 months of age (Macauley et al,
2008). Dexamethasone treatment prevented Purkinje cell loss to a
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significant extent (59% increased in the number of cells per area
unit) (Supplementary Fig 1B). Finally, we ought to determine
whether dexamethasone effects resulted in functional improvement.
The dendritic spine phenotype in the hippocampus moved us to
monitor spatial memory governed by this brain areas using the
Y-maze test (Cognato et al, 2010). The time spent in the novel arm,
indicative of memory ability, was indeed 2.7-fold reduced in the
ASMko females compared to wt (wt: 104  10 s; ASMko:
38  5 s). Dexamethasone treatment significantly increased this
time by two-fold in ASMko females (79  9 s) indicating improved
spatial memory. Given the benefitial effects of dexamethasone
observed in the cerebellum (Supplementary Fig 1B) and because
ataxia is evident in ASMko mice at 4 months of age (Horinouchi
et al, 1995; Macauley et al, 2008), we investigated the impact of
dexamethasone treatment in ASMko female motor coordination
using the vertical pole test (Ogawa et al, 1985). While 100% wt
females completed the test in <50 s none of the ASMko females did
it (Supplementary Fig 1C). Notably, 63% of dexamethasone treated
ASMko females performed the test in <50 s. Analysis of the data in
a cumulative frequency graph clearly showed the distribution of wt,
ASMko treated and ASMko non-treated mice in three differentiated
groups (Supplementary Fig 1C).
Altogether, the results obtained in vivo demonstrate the effi-
ciency of oral treatment with dexamethasone to revert dendritic
spine molecular and morphological anomalies, to prevent cerebellar
neuronal death and to amelliorate behavioural deficits in ASMko
mouse females.
Discussion
The work presented here makes three main contributions: (i)
describes the aberrant phenotype of dendritic spines in the ASMko
mouse, which is a model for NPA; (ii) characterizes the molecular
mechanism underlying this aberrant phenotype; (iii) provides with
pharmacological strategies to revert the anomalies in vitro and in
vivo. We believe these contributions help to understand the yet
poorly characterised role of lipids in synapses and open new thera-
peutical venues for the currently untreatable NPA.
Our results identify an actin regulatory pathway in dendritic
spines, which links a plasma membrane lipid (SM), its catabolic
enzymes (ASM and NSM), neurotransmitter receptors (mGluRs
type I) and a small GTPase (RhoA) and its effectors (ROCK and
profilinIIa). This pathway highlights a previously unknown influ-
ence of SM and sphingomyelinases on the dendritic spine actin cyto-
skeleton. Alterations in this pathway result in the spine anomalies
we found in mice lacking ASM. Although the loss of ASM has a sim-
ilar effect in dendritic spines of neurons analyzed in different brain
areas, i.e. reduction in their size, the extent of size reduction varies.
In neurons of the cortex this is such that it leads to the disappear-
ance of these membrane protrusions. The differences among neuro-
nal populations might be due to variations in the time of exposure
or sensitivity (i.e. basal levels of SM, robustness of compensatory
mechanisms) to the increased SM levels. Further studies are
required to address this issue.
We demonstrate that SM accumulation impairs the membrane
binding and activation of the RhoA pathway, which plays a key role
in dendritic spine actin polymerization (Schubert et al, 2006). Gross
topological SM-induced alteration of the synaptic membrane or defi-
cient addition of lipid moieties to RhoA (essential for the binding of
RhoGTPases to the plasma membrane (Newman & Magee, 1993),
could hurdle RhoA membrane attachment. However, these possibili-
ties would not explain the specificity of the binding impairment for
RhoA. In fact, cdc42 and Rac are not altered despite they require
similar processing for their membrane attachment than RhoA and
would likely be affected by gross topological alterations. In con-
trast, interaction with mGluR1/5 has been shown only for RhoA
(Schubert et al, 2006). We thus propose that the low levels of
these receptors at the synaptic membrane could confer specificity
to the deficient membrane binding observed for this GTPase. Our
results indeed underscore the influence of SM on the levels
of mGluR1/5 in synaptic membranes. Cholesterol-sphingolipid
enriched domains, rafts, regulate the expression of these receptors
at the neuronal surface (Francesconi et al, 2009). In addition, the
absence of ASM alters neuronal raft composition and functionality
as evidenced by the impaired endocytosis and altered distribution
of raft components in polarized hippocampal neurons (Galvan
et al, 2008). Hence, it is possible that alterations in raft lipid
composition (i.e. increased SM levels) have an effect on the
stability and internalization of mGluR1/5 at the ASMko synaptic
membrane, therefore affecting RhoA membrane distribution. In
support for the involvement of raft alterations in the aberrant
molecular phenotype we observed that, although raft abundance
does not appear to be significantly affected since the raft bona
fide marker flotillin is not altered, the presence of RhoA in raft
domains is reduced in ASMko synaptosomes compared to wt
(Supplementary Fig 6).
A surprising conclusion arising from our work is the relevant
influence that ASM has on the lipid and protein composition of syn-
aptic membranes, despite being a lysosomal enzyme (Stoffel, 1999).
However, the presence of a pool of ASM has been reported at the
plasma membrane (Grassme et al, 2001) and we consistently
observed high SM levels at this cellular site in ASMko cultured hip-
pocampal neurons and in non-lysosomal membranes derived from
ASMko mouse brain extracts (Galvan et al, 2008). Here we extend
these findings and describe that ASM deficiency also affects the lipid
composition of postsynaptic membranes. The question arises about
how an enzyme with an acidic optimal working environment may
function at the neutral environment of the plasma/synaptic mem-
brane. Data showing the ability of ASM to degrade SM within LDL
particles at physiological pH values (Schissel et al, 1998) and the
possibility that acidified microenvironments may exist at the cell
surface (Bourguignon et al, 2004; Steinert et al, 2008) could explain
this apparent inconsistency. It is also important to note that a very
limited activity of this enzyme (1–2%) appears to be sufficient to
avoid the severe neurological symptoms of NPA patients. In fact,
this range of ASM residual activity distinguishes between the type A
and the non-neurological type B forms of Niemann Pick disease
(Schuchman, 2009). Our findings indicate that although ASM is nec-
essary for neuronal function little activity would be enough to fulfil
its task. Thus, therapies for NPA aimed to increase sphingomyelin-
ase activity at the plasma/synaptic membranes might be effective
even with low efficiency.
Our results suggest that one such strategy is the enhancement of
NSM activity. We report that two NSM activators, the active form of
vitamin D and the glucocorticoid dexamethasone, have the ability to
Ana I Arroyo et al Synaptic rescue in Niemann Pick type A EMBO Molecular Medicine
ª 2014 The Authors EMBO Molecular Medicine Vol 6 | No 3 | 2014 405
reduce the amount of SM by increasing NSM protein levels and
activity at synapses and to rescue aberrant phenotypes in vitro.
Although with low efficiency, both compounds cross the brain
blood barrier (Pardridge et al, 1985; Stumpf et al, 1989; Stumpf,
2012), and have been already used for long-term treatment of differ-
ent human diseases (Bonthius & Karacay, 2002; Holick, 2005; Cole,
2006). We report that in vivo treatments by oral administration of
dexamethasone to ASMko females significantly reduced synaptic
SM and increased NSM protein levels, reverted aberrant synaptic
molecular and morphological phenotypes, prevented neuronal
degeneration and improved functional deficits. We found a similar
tendency in dexamethasone treated males but the effects were not
statistically significant. The different outcome between females and
males might respond to a less efficient NSM enhancement in the
later, in turn preventing SM reduction (compare Fig 6A and B with
Supplementary Fig 5). Our results evidence that dexamethasone
induces the transcriptional activation of the enzyme in the brains of
ASMko treated females. The fact that we observe increased NSM
levels upon in vitro treatment of isolated synaptosomes suggests
that local transcription might be taking place. Further work will
detailed how dexamethasone enhances NSM transcription. A likely
possibility would involve glucocorticoid (GC) receptors, for which
dexamethasone is an agonist and which expression levels are differ-
ent in males and females and could explain the different response
between genders. Our data in synaptosomal preparations and the
recently reported presence of GC receptors in dendritic spines (Jafari
et al, 2012), would support a direct effect of dexamethasone in syn-
apses. Although basal or slightly high GC concentrations are needed
for learning and memory processes, chronic excess in GC levels has
adverse effects in the nervous system including atrophy of neuronal
processes and disruption of plasticity (Sapolsky, 1999). This is in
apparent contradiction with the positive effects we observe in dexa-
methasone treated ASMko mice and raises concern about the possi-
ble long-term exposure of ASMko neurons to this synthetic GC.
However, expression of GC receptors at dendritic spines is increased
by activation of mGluR type 1 (Jafari et al, 2012), which levels we
find reduced in ASMko synapses. It might be that response to GC is
chronically impaired in ASMko mice and that the long-term expo-
sure to a GC receptor agonist restores this response to normal, not
high, levels resulting in the improvement and not in the impairment
of synaptic events.
Alternative to a direct effect, the influence of the orally adminis-
tered dexamethasone in synaptic SM levels and function might be
indirect through its immunomodulatory properties. While the
majority of studies have emphasized the immunosuppressive role of
GCs, immunoenhancement effects can occur through the differential
modulation of cytokine levels (Wilckens, 1995). Indeed, while acute
peritoneal dexamethasone administration resulted in reduced levels
of cytokines in the injured hippocampus, dexamethasone treatment
prior to injury increased cytokine expression including that of TNFa
(Bruccoleri et al, 1999). There is increasing evidence that pretreat-
ment with this cytokine may protect neurons against injuries (Figiel,
2008). Interestingly, TNFa is also a potent activator of NSM at syn-
apses playing a role in neurotransmitter receptor clustering and syn-
aptic plasticity (Wheeler et al, 2009). Therefore, a dexamethasone-
induced increase of TNFa levels might account for the enhanced
NSM activity and reduced SM levels at synapses of ASMko treated
mice. It might thus be that TNFa exerts two positive actions in the
ASMko brains: facilitating synaptic plasticity and preventing neuro-
nal damage.
A third, not excluding, possibility would involve the anti-
inflammatory effects of dexamethasone (Laste et al, 2013). To
explore this possibility we treated ASMko synaptosomes or ASMko
females with ibuprofen, a non-steroid anti-inflammatory drug
(NSAID). Using the same protocols as for dexamethasone we did
not see any difference in SM levels or RhoA membrane binding in
vitro (Supplementary Fig 7A). Synaptosomes derived from ASMko
females after oral administration of ibuprofen for 2.5 months
showed a tendency for SM reduction and increased RhoA mem-
brane binding (Supplementary Fig 7B). However, the differences
were not statistically significant with respect to non treated mice.
These results do not allow us to rule out that anti-inflammatory
effects of dexamethasone are involved in the positive effects
observed in the treated ASMko mice but suggest that, at least in
the conditions tested, these effects are not sufficient to restore the
normal phenotype. In any event, these results encourage research
aimed to determine the potential benefits of the use of NSAIDs for
NPA treatment.
Finally, the present results together with other recent reports
(reviewed in Ledesma et al, 2011) stress the view that NPA
should not be regarded simply as a lysosomal lipid storage disease.
Sphingolipid alterations at the plasma and synaptic membranes
likely contribute, as much or even more, to the neuronal pathol-
ogy than the accumulation of these lipids in lysosomes. Therefore,
therapies aimed to correct these alterations should be taken into
account.
Figure 5. In vitro treatments with 1a, 25-dihydroxivitamin D3 or dexamethasone diminish SM amount, increase NSM protein levels and activity, and restore
RhoA membrane binding and filamentous actin levels in ASMko synapses.
A Western blot of NSM protein levels in total (Tot) and synaptosomal (Syn) fractions from wt and ASMko mice brains containing the same amount of protein.
B Mean  s.d. of SM levels (nmol/mg protein) in ASMko synaptosomes treated or not with 1a, 25-dihydroxivitamin D3 (VitD3) or dexamethasone (DM) (n = 3,
*PvitD3 = 0.04; *PDM=0.033).
C Western blot of NSM and tubulin levels in ASMko synaptosomes treated or not with VitD3 and dexamethasone. Graph shows mean  s.d. of NSM protein levels
normalized to tubulin (n = 3, P = 0.025). Graphs to the right show mean  s.d. of NSM activity in ASMko synaptosomes treated or not with dexamethasone (n = 3,
*P = 0.032).
D Western blots of RhoA levels in supernatants (S) and pellets (P) after 100,000 g centrifugation of ASMko synaptosomes treated or not with VitD3 or DM. Graph
shows mean  s.d. of the RhoA ratio pellet/supernatant in the treated samples as percentage of ASMko non treated samples that were considered 100% (n = 3;
*PvitD3 = 0.042; **PDM = 0.001).
E Top: Dendrites from ASMko neurons non treated or treated with vitaminD3 or dexamethasone stained for MAP2 (blue), PSD95 (red), and phalloidin (green); bottom:
phalloidin staining only. The graph shows mean  s.d. of phalloidin fluorescence intensity per spine area (n = 250 dendritic spines from 3 independent cultures,
**PvitD3 = 0.001; ***PDM = 0.0008). Bars: 5 lm.
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Figure 6. Oral treatment with dexamethasone increases brain NSM mRNA and protein levels and reverts molecular, morphological and functional
alterations in ASMko females.
A Mean  s.d. of SM levels (nmol/mg protein) in synaptosomes from ASMko females treated or not with dexamethasone (n = 10; *P = 0.03). Western blot of NSM and
tubulin levels in synaptosomes derived from ASMko females treated or not with dexamethasone. Graphs show mean  s.d. of NSM protein (normalized to tubulin)
and mRNA levels (n = 10, *PNSM prot = 0.024; *PNSM mRNA = 0.03).
B Western blots shows RhoA levels in supernatants (S) and pellets (P) after 100 000 g centrifugation of synaptosomes from ASMko females treated or not with
dexamethasone. Graph shows mean  s.d. of the RhoA ratio pellet/supernatant in synaptosomes from ASMko females treated or not with dexamethasone (n = 10,
*P = 0.01).
C Electron micrographs of synapses in the hippocampal CA1 stratum radiatum of ASMko females treated or not with dexamethasone. Spines are indicated by
asterisks. Graph shows mean  s.d. of PSD length in lm (n = 70 synapses in each of 3 mice per condition, *P = 0.031).
D Results of the Y-maze test in wt, ASMko and dexamethasone ASMko treated females. Graph shows mean  s.d. of the time (in seconds) spent by the mice in the
novel arm (n = 7; **Pko vs wt = 0.009, *PDMko vs ko = 0.021).
EMBO Molecular Medicine Synaptic rescue in Niemann Pick type A Ana I Arroyo et al
EMBO Molecular Medicine Vol 6 | No 3 | 2014 ª 2014 The Authors408
Materials and Methods
Materials
Antibodies against the following molecules were used for Western
blots: RhoA (rabbit polyclonal 67B9 Cell Signaling Technology Inc.,
Danvers, MA, USA), ROCK (mouse monoclonal clone 21 BD trans-
duction laboratories, Becton, Dickinson and Company, Franklin
Lakes, NJ, USA), Profilin IIa (rabbit polyclonal, a gift from C.G.
Dotti laboratory, CBMSO Madrid, Spain), alpha-tubulin (mouse
monoclonal 7291; Abcam plc, Cambridge Science Park, Cambridge,
UK), Synaptophysin (mouse monoclonal Boehringer), PSD95
(mouse monoclonal Upstate Biotechnology), mGluR1 (Rabbit poly-
clonal 445870; Calbiochem, EMD Millipore Corporation, Billerica,
MA, USA), mGluR5 (Mouse monoclonal 5675; Millipore, EMD Milli-
pore Corporation), NSM (mouse monoclonal sc-166637; Santa Cruz
Biotechnology Inc., Dallas, TX, USA), Calbindin (rabbit polyclonal
PC253L; Merck Millipore, Merck KGaA, Darmstadt, Germany). Goat
anti-rabbit and Rabbit anti-mouse HRP-conjugated antibodies
(Dakocytomation) were used as secondary antibodies.
Mice
A breeding colony was established from a couple of ASM hetero-
zygous C57BL/6 mice (Horinouchi et al, 1995), kindly donated by
E.H. Schuchman (Mount Sinai School of Medicine, New York). Male
littermates of 4–6 months of age wt and ASMko mice were com-
pared. All procedures involving the use of animals were conducted
according to guidelines specified for the animal protection and
welfare by the Spanish Ministry of Agriculture.
DiOlistic labeling of dendritic spines
For diOlistic imaging of dendritic spines, mice (four for each geno-
type) were anesthetized and perfused with 4% paraformaldehyde in
phosphate buffer (PB, 0.1 M pH 7.4). The brains were postfixed,
washed in PB and cut into 300-lm sagittal sections on a vibratome
(Leica VT 1000S; Leica Microsystems GmbH, Wetzlar, Germany).
Fluorescent labeling of brain sections was done according to a modi-
fied protocol of the original diOlistic labeling (Pavlowsky et al, 2010)
described by Gan et al (2000). Briefly, tungsten particles coated with
1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate
crystals (DiI) were propelled into brain sections from a distance of
0.5 cm using a biolistic ‘Helios gene gun system’ (BioRad Labora-
tories, Inc., Berkeley, CA, USA) at a pressure of 120 psi. A mem-
brane filter with a 3.0 lm pore size (Millipore) was placed between
the gun and the tissue to filter out large clusters of coated particles.
After one single shot, slices were placed in 4% paraformaldehyde for
2 h, washed in PB and mounted on slides. A confocal microscope
(Zeiss LSM-5 Pascal, Germany) was used to image the labeled struc-
tures. Optical sections were collected using a 40 × immersion oil
objective with a digital zoom of 4 ×. At least 10 z-stack images con-
sisting of 10–15 sections (512 × 512 pixels, 80–100-lm-long den-
dritic segments) spaced 0.5 lm apart were collected for each animal
and for each area analyzed to generate the data set. Spine density
was analyzed in CA1 neurons of the hippocampus and in pyramidal
neurons of the S1 cortex. Dendritic segments and spines were
analyzed quantitatively by using 3D image stacks using ImageJ soft-
ware 1.34S (Wayne Rasband, National Institute of Health, Bethesda,
MD, USA, public domain). All dendritic protrusions with a clearly
recognizable neck connected to the shaft of the dendrite were
counted as spines. Spine number and dendritic length were mea-
sured by projecting all the stacks of an image into a single plane
(maximum projection) with the observer blind to the experimental
conditions. The raw data obtained in ImageJ (Image processing and
Analysis in Java, Developed by Wayne Rasband, National Institute
of Health) were exported to Microsoft Excel for further analysis.
Electron microscopy
Mice were anesthetized with an intraperitoneal injection of keta-
mine-xylazine 1:1 (0.1 ml/kg) and perfused through the left ventricle
with a mixture of paraformaldehyde (4%) and glutaraldehyde (2%)
in PB. Brains were postfixed in the same solution for 4 h. The dorsal
hippocampus or the cerebellum were cut into transverse slabs that
were postfixed in 1% osmium tetroxide (in 0.1 M cacodylate buffer),
dehydrated in ethanol and embedded in Epon-Araldite. Serial ultra-
thin sections of the CA1 region or the molecular cerebellar layer were
collected on pioloform-coated, single-hole grids, and stainedwith ura-
nyl acetate and lead citrate. The sections were analysed with a JEM-
1010 transmission electron microscope (Jeol, Japan) equipped with a
side-mounted CCD camera Mega View III from Olympus Soft Imaging
System GmBH (Muenster, Germany). Synapses were sampled ran-
domly in the proximal part of stratum radiatum and photographed at
a magnification of ×75.000 (~70 synapses per mouse, n = 3 mice per
group). The area of dendritic spines and the length of the PSD were
measuredwith the AnalySIS software (Soft Imaging SystemGmBH).
Synaptosomal isolation
The protocol has been well described in Schubert et al (2006) and is
based on methods set by Cohen et al (1977) and Carlin et al (1980).
Briefly, mouse brains were homogenized in buffer A (0.32 mM
sucrose, 1 mM MgCl2, 0.5 mM CaCl2, 1 mM NaHCO3, protease
inhibitors) and centrifuged at 1400 g for 10 min to obtain superna-
tant S1 and pellet P1. P1 was homogenized in buffer A and centri-
fuged at 700 g for 10 min. The resulting supernatant was combined
with the previous S1 and centrifuged at 13 800 g for 10 min. The
obtained supernatant (S2) was centrifuged at 17 000 g for 1 h. The
resulting supernatant (S3) constitutes the cytosolic fraction. The
resulting pellet resuspended in buffer B (0.32 mM sucrose, 1 mM
NaHCO3, 1 mM EGTA, 1 mM dithiothreitol, protease inhibitors) is
the crude synaptosomal fraction. To obtain the pure synaptosomal
fraction, the crude fraction was loaded on a discontinuous sucrose
gradient (1 and 1.4 M sucrose) and centrifuged for 65 min at
82,500 g. The pure synaptosomal fraction was recovered from the
interphase between 1 and 1.4 M sucrose. To obtain a fraction
enriched in postsynaptic membranes (PSD), the protein amount was
calculated in the pure synaptosomal fraction, and a 4 mg/ml solu-
tion was prepared with buffer B. An equal volume of a solution com-
posed of Triton X-100, 0.5 mM Hepes/KOH, and protease inhibitors
was added and stirred for 15 min on ice. The sample was centrifuged
at 28,000 g for 40 min to obtain supernatant LS1. LS1 was centri-
fuged at 165 000 g for 120 min to obtain pellet LP2. LP2 was then
homogenized in buffer B and loaded onto a discontinuous sucrose
density gradient composed of 1.0, 1.5, and 2.1 M sucrose and centri-
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fuged at 201,800 g for 60 min. The PSD fraction was obtained from
the interphase between the sample and 1.0 M sucrose.
Lipid analysis
For the mass lipid analysis of postsynaptic enriched fractions (PSD)
lipid extracts were prepared as described in Galvan et al (2008) and
analyzed for phospholipids (organic phosphate) (Van Veldhoven &
Bell, 1988) or enzymatic quantification of cholesterol (Van Veldho-
ven et al, 1998). To quantify SM, lipid extracts were dried in pres-
ence of detergent (Thesit), and SM was subsequently converted into
choline by means of sphingomyelinase, alkaline phosphatase, and
coupled to the production of fluorescence with choline oxidase, per-
oxidase and homovanillic acid as modified from Hojjati and Jiang
(2006) and optimized for extracts (Van Veldhoven P.P. and De
Schryver E., unpublished data).
Synaptosomal treatments
For stimulation crude synaptosomal fractions were incubated for
3 min at 37°C under gentle agitation with 5 mM KCl (control) or
55-mM KCl (stimulated). Reactions were stopped by placing the
samples on ice.
To modulate SM levels in synaptosomes, freshly isolated pure
synaptosomal fractions were incubated at 37°C for 1 h under gen-
tle agitation either with 100 lg/ml SM (Sigma-Aldrich, Co., St.
Louis, MO, USA) (added from a stock prepared in ethanol) to
increase the lipid levels or with 0.1 lM 1a, 25-dihydroxyvitamin
D3 (Sigma-Aldrich) or dexamethasone (Sigma-Aldrich) to decrease
them. To analyze the effect of the treatments on the membrane
attachment of RhoA and its effectors, treated and non treated
samples were centrifuged at 100 000 g and 4°C for 1 h. Proteins
in supernatants and pellets were resolved by SDS-PAGE and elec-
troblotted to nitrocellulose membranes. These were incubated
with specific primary antibodies and with peroxidase-linked sec-
ondary antibodies. Chemiluminescent signal in the Western blot
was detected by ECL (GE Healthcare Co., Fairfield, CT, USA) and
quantified under non saturated conditions using a densitometer
and the software Quantity One.
Hippocampal neuronal cultures and treatments
Primary cultures of hippocampal neurons were prepared from wt
and ASMko mice brain embryos as described in Goslin & Banker
(1991). For our experiments hippocampal neurons were kept in
culture for 15 days or more when they have reached full synapse
maturation. SM levels were modulated by several means: (i) addi-
tion to wt neurons of 40 lM SM (Sigma-Aldrich), which was added
from a stock prepared in ethanol that ensured a final ethanol
concentration of less that 1% in the neuronal medium to avoid
toxicity. Same amount of ethanol without SM was added to control
neuronal cultures; (ii) incubation of ASMko neurons with Bacillus
aureus Smase (Sigma-Aldrich) at 0.1 unit/100 ll medium (as
indicated in Galvan et al, 2008). For the activation of Neutral sphin-
gomyelinase 1a, 25-dihydroxyvitamin D3 or dexamethasone were
added everyday to the culture medium at a final concentration of
0.1 lM, starting at 9DIV until 15 DIV. To determine the amount of
filamentous actin in all the aforementioned experiments, neurons
were fixed in PFA/SEM buffer (4% paraformaldehyde, 0.12 M
sucrose, 2 mM EGTA and 2 mM MgCl2 in PBS) for 10 min,
quenched with 50 mM ammoniun chloride and extracted with 0.1%
Triton X-100 at RT. Filamentous actin was labelled by incubation
with TRITC-conjugated phalloidin (Sigma-Aldrich) as in Schubert
et al (2006). Samples were analyzed in a Leica fluorescence micro-
scope. Phalloidin associated fluorescence was quantitated in den-
dritic spines identified, by triple labelling immunofluorescence, as
PSD95 positive protrusions derived from the dendritic shaft, which
was labelled with MAP2. Pixel intensity was determined with
ImageJ software. Mean intensity in spines was calculated per area
unit.
Rhotekin binding assay
The EZ-detectTM Rho Activation kit (Pierce Protein Biology Products;
Themo Fisher Scientific Inc., Rockford, IL, USA) was used to deter-
mine the affinity of RhoA to its downstream effector Rhotekin and
thus its activity. Fresh crude synaptosome preparations from age-
matched wt and ASMko mice containing 500 lg of protein were pro-
cessed, in parallel, following the manufacturers instructions. The
resulting samples were analyzed by Western blot using an antibody
against RhoA.
Raft isolation
Synaptosomes were incubated in TNE buffer (100 mM Tris, 2 mM
NaCl, 10 mM EDTA, pH 7.4) containing 0.5% Triton X-114 and
protease inhibitor cocktail (complete EDTA-free; Roche, Basel,
Switzerland)(40 min, 4°C), then brought to 60% sucrose. A 35 and
5% sucrose step gradient in TNE was overlaid on samples and
ultra centrifuged (19 h, 73 000 g). After centrifugation, 13 fractions of
1 ml each were collected from top to bottom of the tube. Detergent-
insoluble material (rafts) was obtained in the lighter fractions (1–7).
Immunoprecipitation
Synaptosomal preparations were precleared with G-Sepharose beads
and incubated or not with 3 lg anti-RhoA antibody for 1 h at 4°C.
Subsequently, protein G-Sepharose beads were added and samples
were incubated overnight at 4°C under gentle rotation. Samples
were then washed twice (20 min each washing) with immunopre-
cipitation buffer (1% Triton X-100, 100 mM NaCl, 2 mM EDTA,
10 mM Tris–HCl, 1 mM Na3VO4, pH 7.5 and protease inhibitors),
twice with high salt buffer (same as immunoprecipitation buffer but
with 500 mM NaCL and no Triton X-100) and once with low salt
buffer (same as immunoprecipitation buffer but without NaCl and
TritonX-100). Beads were pelleted in between washes by centrifuga-
tion at 1600 g for 30 s. After the final wash, beads were pelleted
down by high-speed centrifugation and the immunocomplexes
released from beads and analyzed by Western blot using anti-
mGluR1 or anti-mGluR5 antibodies.
Oral treatment with dexamethasone and ibuprofen
Wt and ASMko mice were divided by gender in groups of ten animals
each. Treatments started immediately after weaning when mice were
1 month old. Dexamethasone dissolved in ethanol or ibuprofen
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(pirexin solution, Juventus laboratories) was added to the drinking
water at a concentration of 1.5 lg/ml and 1 mg/ml (as in Ezell et al,
2012), respectively. Considering that the regular daily consumption
of water per mice is 4 ml and the average weight is 20 g this
concentration ensured the consumption per mouse of approxi-
mately 0.3 lg/g/day dexamethasone (ethanol consumption was
lower than 5 ll/mouse/day). Non-treated males and females were
given ethanol in their drinking water at the same concentration
than the dexamethasone-treated mice. The drinking water with or
without dexamethasone or ibuprofen was renewed every 3 days.
Treatments went on for 2.5 months. At this time point mice were
evaluated in behavioural tests (see below). They were subse-
quently sacrificed for synaptoisolation from their brains and
biochemical analysis.
Measurement of NSM mRNA
Total RNA from brain cortex homogenates was obtained by Trizol
Reagent (Ambion /RNA. Life Technologies Co., Grand Island, NY,
USA) and chloroform extraction. RNA was further cleaned up using
Rneasy Mini kit (Qiagen, Hilden, Germany). RNA concentration was
estimated by absorbance at 260 nm using a Nanodrop ND-100 (Ther-
moscientific; Themo Fisher Scientific Inc.). The retrotranscription to
first strand cDNA war performed using RevertAid H Minus First
Strand c DNA Synthesis kit from Thermo Scientific. qPCR was per-
formed using GoTaq qPCR Master Mix (Promega Co., Madison, WI,
USA) and ABI PRISM 7900HT SDS (Applied Biosystems; Life Tech-
nologies Co.). For the detection of NSM2 transcripts the following
primers (Sigma-Aldrich) were used: Nsm2_fw: 5′-TGCTGGACACA
AACGGTCT; Nsm2_rev: 5′ – GTTGTCCGGGGTACACACAT. The
three housekeeping genes GAPDH, GUSB and HPRT1 were used as
endogenous controls.
NSM activity
NSM activity was measured in synaptosomal extracts with the fluori-
metric kit from Cayman Chemical Company (Sphingomyelinase
Flourimetric assay kit, 10006964). Resorufin fluorescence was ana-
lyzed using the fluorometer FLUOstar OPTIMA from BMG LABTECH
GmbH (Ortenberg, Germany).
Neuronal death
Neuronal death was monitored in Purkinje cells of ASMko dexa-
methasomne treated or non treated females by immunofluorescence
of brain tissue using an antibody against calbindin, which is a spe-
cific marker for these neurons. Images were obtained as Z-stacks
using a confocal LSM 510 Meta coupled to a microscope Axiovert
200 (Zeiss). Number of calbindin positive cells were counted per
area unit using the Image JA 1.45b software.
Behavioural tests
The Y maze test was performed as in Cognato et al (2010). Briefly,
during a first trial (training, 5 min), mice were allowed to explore
only two arms (start and the other arm) with the third arm (novel
arm) closed. For the second trial, mice were placed back in the
same starting arm, with free access to all three arms for 5 min. The
time spent in the novel arm was counted. The vertical pole test was
performed as previously described (Ogawa et al, 1985). Briefly,
mice were placed head-downward at the top of a vertical rough-sur-
faced pole (diameter 8 mm; height 55 cm) and let descend in a
round of habituation. Then, mice were placed head-upward at the
top of the pole. The total time until they descended to the floor was
recorded with a maximum duration of 190 s. Ten age-matched wt,
ASMko or dexamethasone-treated ASMko females were evaluated.
Mice that did not move from the top of the pole after 190 s were
not scored.
Statistical analysis
Student’s t-test and one-way ANOVA were used for statistical analy-
sis of the data. P values lower than 0.05 were considered significant.
In the figures asterisks indicate P values as follows: *< 0.05;
**< 0.02; ***< 0.001. For the analysis of motor coordination after
dexamethasone treatment the chi-squared test was utilized. P values
lower than 0.05 were considered significant.
The paper explained
Problem
Although lipids are increasingly well recognized as key players in syn-
aptic function, little is known about the molecular basis of their
involvement. This information is essential to understand the etiology
of the many lipidoses leading to cognitive impairment, which cur-
rently have poor prognosis. Niemann Pick disease type A (NPA) is an
untreatable sphingolipidosis caused by loss of function mutations in
the acid sphingomyelinase (ASM) gene leading to cellular sphingomye-
lin (SM) accumulation, severe mental retardation and death in early
childhood. Although therapeutical strategies aimed at reducing SM
levels have been tested in mice lacking ASM, which mimic the disease,
the impact on brain pathology has been limited.
Results
We show that high SM levels at synapses of sphingomyelinase knock
out mice (ASMko) diminish dendritic spine number and size by reduc-
ing filamentous actin. The molecular mechanism underlying these
defects involves reduction of group 1 metabotropic glutamate recep-
tors levels, which impairs the binding of the small GTPase RhoA to
the postsynaptic membrane and the activation of its downstream ef-
fectors RockII and profilinIIa. Pharmacological activators (Vitamin D3
and dexamethasone) of the neutral sphingomyelinase reduce the lev-
els of synaptic SM and restore RhoA membrane binding and filamen-
tous actin levels in vitro. Oral treatment with dexamethasone causes
similar effects in ASMko females by restoring dendritic spine size,
preventing neuronal damage and leading to functional improvement.
Impact
Our study identifies a novel pathway by which a lipid (SM) and its
catabolic enzymes modulate actin cytoskeleton in dendritic spines.
We describe the alterations of this pathway in a mouse model for
NPA and prove the efficiency of a pharmacological strategy to revert
these alterations in vitro and in vivo. The fact that this strategy is
based on the oral administration of dexamethasone, a compound that
crosses the brain blood barrier and is already used for long-term
treatments in different human diseases, enhances the possibilities of
clinical applicability to NPA patients. Importantly, our findings could
be relevant for patients with neurological disorders other than NPA
that also exhibit aberrant SM accumulation.
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